Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
Open Access
- 1 June 2005
- journal article
- clinical trial
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 8 (2) , 194-200
- https://doi.org/10.1038/sj.pcan.4500799
Abstract
Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide (‘Casodex’†) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150 mg/day in addition to radical prostatectomy, radiotherapy or watchful waiting for T1b–4, any N, M0 prostate cancer. In Trial 24, at 5.1 y median follow-up, the addition of bicalutamide significantly (PP=0.746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer.Keywords
This publication has 19 references indexed in Scilit:
- BICALUTAMIDE 150 MG IN ADDITION TO STANDARD CARE IN PATIENTS WITH LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM THE SECOND ANALYSIS OF THE EARLY PROSTATE CANCER PROGRAM AT MEDIAN FOLLOWUP OF 5.4 YEARSJournal of Urology, 2004
- BICALUTAMIDE (150 MG) VERSUS PLACEBO AS IMMEDIATE THERAPY ALONE OR AS ADJUVANT TO THERAPY WITH CURATIVE INTENT FOR EARLY NONMETASTATIC PROSTATE CANCER: 5.3-YEAR MEDIAN FOLLOWUP FROM THE SCANDINAVIAN PROSTATE CANCER GROUP STUDY NUMBER 6Journal of Urology, 2004
- Cost-Effectiveness Analysis of Bicalutamide (Casodex™)* *Casodex™ is a registered trademark for AstraZeneca. for Adjuvant Treatment of Early Prostate CancerValue in Health, 2004
- THE ECONOMIC BURDEN OF METASTATIC AND PROSTATE SPECIFIC ANTIGEN PROGRESSION IN PATIENTS WITH PROSTATE CANCER: FINDINGS FROM A RETROSPECTIVE ANALYSIS OF HEALTH PLAN DATAJournal of Urology, 2004
- The psychological impact of cancer on patients’ partners and other key relativesEuropean Journal Of Cancer, 2003
- Cancer Fear and Mood Disturbance After Radical Prostatectomy: Consequences of Biochemical Evidence of RecurrenceJournal of Urology, 2003
- Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer ProgramJournal of Urology, 2002
- CONSERVATIVE MANAGEMENT OF PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERA: THE INCIDENCE AND TIME COURSE OF SUBSEQUENT THERAPYJournal of Urology, 2001
- Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progressionUrology, 2001
- Complications of advanced prostate cancerUrology, 1999